Biosimilar Patent Thicketing Has Cost US $7.6bn

 
• By Akriti Seth
  
Syringe
US patients, taxpayers and the healthcare system are bearing the costs of patent schemes: AAM • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products